According to Dr Arjun Dang, the central lab at Dr Dangs conducted tests in all three trial phases of the Corbevax COVID-19 vaccine.

Dr. Arjun Dang, CEO, Dr Dangs Lab, applauded the announcement on Tuesday. COVID-19 vaccine from Biological E Limited is the first indigenously developed protein-subunit vaccine against COVID19.

New Delhi, India, December 29: Dr. Arjun Dang, CEO, Dr Dangs Lab, applauded the announcement on Tuesday that the Drug Controller General of India (DCGI) approved two new COVID-19 vaccines and one anti-viral drug for immediate use, saying that they are the laboratory of choice for an end-to-end solution to the Corbevax vaccine.Dr. Arjun Dang said that this required close cooperation with investigating sites, principal investigators, and efficient handling of pan-India logistics.The COVID-19 vaccine from Biological E Limited is the first indigenously developed protein-subunit vaccine against COVID19, which uses the spike protein's receptor-binding domain as the vaccine antigen.For many years, the protein subunit class of vaccines have been used successfully against a variety of viral pathogens and are well-known for their Dr. Dangs Lab in New Delhi performed and participated in the screening and immunogenicity studies for all three phases in accordance with strict quality standards set by GCLP guidelines as required by regulatory authorities, Dr. Arjun Dang said.